Antidepressant, antioxidant and anti-inflammatory effects of curcumin in adults diagnosed with major depressio

Phase 3

Completed

• Conditions: Depression; Mental Health - Depression

• Registration Number: ACTRN12612001260819
• Lead Sponsor: Murdoch University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-12-03
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1. Male or female aged between 18 and 65 years
2. Suffering from major depression (mild to moderate severity) as assesed by the Mini International Neuropsychiatric interview
3. Medication-free for at least 4 months (except pharmaceutical antidepressants and contraceptive pill)
4. Non-smoker

Exclusion Criteria

1. Suffer from a diagnosable mental health disorder other than depression e.g., eating disorder, psychosis/ schizophrenia.
2. Suffer from medical illnesses including diabetes, autoimmune diseases, cardiovascular disease, hypertension, chronic fatigue syndrome, asthma.
3. Pregnant or intend to fall pregnant
4. Currently breastfeeding
5. Have suffered from an infection or illness over the last month (includes the common cold)
6. Currently take any antiplatelet (e.g., Aspirin, non-steroidal anti-inflammatories, clopidogrel, dipyridamole, abciximab, tirofiban) and anticoagulant medications (e.g., Warfarin, rivaroxaban, dabigatran etexilate)
7. Have been diagnosed with any coagulation disorder such as Haemophilia, Thrombocytopenia, Von Willebrand's disease and Hypoprothrombinemia.
8. Suffer from a recent history of severe bruising, excessive bleeding following an injury, abnormal blood count (including platelets counts), profuse nosebleeds, and excessively prolonged or heavy menstrual bleeding

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in anxiety levels as assessed by the Spielberger state-trait anxiety inventory (STAI)[Weeks 1, 4 and 8];Change in general health as assessed by SF-36 Health Survey[Weeks 1, 4 and 8];Change in depression score as assessed by the Inventory of Depressive Symptomatology (IDS-SR30)[Weeks 1, 4 and 8]

Secondary Outcome Measures

Name	Time	Method
Change in salivary cortisol awakening response[Weeks 1 and 8];Changes in inflammatory and oxidative stress markers as assed in blood and urine[Weeks 1 and 8]